Published in Blood Weekly, March 23rd, 1998
The Hybritech Free PSA test is expected to significantly reduce the number of unnecessary prostate biopsies, lower healthcare costs and ease the anxiety of many men over age 50 who are at risk for prostate cancer.
The Hybritech Free PSA test developed by Beckman Coulter detects 95 percent of prostate cancers and is used by physicians to differentiate between prostate cancer and benign prostate conditions, said clinical researchers involved in a recent multi-center study.
Nearly all prostate cancers that are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.